Collaboration with InterAx on new immune oncology drugs
leadXpro AG and InterAx Biotech AG, join forces to discover and optimize new drug lead molecules targeting G-protein coupled receptors.
Stephan Müller
About Stephan Müller
Posts by Stephan Müller:
Watch our 2nd anniversary video
leadXpro celebrates its second anniversary
CTI grants leadXpro startup label
The Swiss Commission for Technology and Innovation CTI awards leadXpro the CTI startup label.
BASF and leadXpro announce research collaboration
BASF and leadXpro AG will join forces to collaborate on the structure-based discovery of new active ingredients by employing single particle cryo-electron microscopy.
leadXpro scientists chart the future of structure based drug discovery
leadXpro AG scientists explore the utility of cutting-edge X-ray technologies for the discovery of new therapeutics.
leadXpro adopts creoptix’ wave technology for ligand characterization
Creoptix and leadXpro AG announce the selection of the Creoptix WAVE technology by leadXpro to strengthen its capabilities for drug discovery aimed at identifying and optimizing drug candidates directed against challenging membrane protein drug targets.
leadXpro and AXXAM collaborate on novel inflammatory GPCR target
leadXpro and AXXAM announce the collaboration for the discovery of small molecular ligands to a novel inflammation related GPCR target.
Structural biology: doors open at the European XFEL
A technology feature by Nature Methods’ technology editor Vivien Marx about free electron lasers to comment on the opening of the European X-ray Free Electron Laser (EuXFEL) in Hamburg, Germany.
New Operational Space and Funding ensures further growth of LEADXPRO
Tripling its physical footprint and with a new funding round secured, leadXpro AG is well-prepared for further development.
GPCR-ligand complex structure within 4 months
In collaboration with a major pharma company, leadXpro AG announced today the successful delivery of multiple GPCR structure determination milestones ahead of schedule.